Replies to post #80080 on Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

News could be released at any time. I.E. License agreement with Becton Dickinson.


We are evaluating a variety of financing options including joint ventures, licensing, debt, equity and grant funding to give the Company sufficient capital to operate over the foreseeable future as our products reach major milestones.

Over the next year, we expect to make significant progress in the following areas:


1) Advancing LymPro through to commercialization sales as an LDT via CLIA;

2) Conducting IND-enabling studies for MANF in the non-human primate model of Parkinson's disease;

3) Completing proof-of-concept studies and preparing to file an IND for MANF in at least one orphan indication;

4) Completing feasibility studies for MANF in diabetes, ischemic heart disease and traumatic brain injury.

We are hopeful to meet a number of other important milestones in our NuroPro and PhenoGuard programs while continuing to evaluate new business opportunities rooted in our deep understanding of the central nervous system. If we achieve these objectives, both our therapeutics and diagnostics subsidiaries will be well positioned to thrive, and in turn the Company will be focused on evaluating ways to capture that value.

[hnbadger1]

"We are evaluating a variety of financing options including joint ventures, licensing, debt, equity and grant funding to give the Company sufficient capital to operate over the foreseeable future as our products reach major milestones."

Sounds to me like they already HAVE options.Some of you guys seem to think that AMBS is on their death-bed over finacing.
As a large shareholder, I was very encouraged by the report.

How many of you own other small-cap biotechs? If you did, you would see that AMBS is doing a great job of meeting goals and keeping shareholder updated. It is not realistic to expect PR's every week and get things done quickly in this field. You need patience and maybe a strong stomach, but I beleive AMBS will reward LONG-TERM shareholders that hold this long term with huge gains.
GLTA AMBS LONGS!!